Injectable composition

A composition of matter produced by the process of:

• a) obtaining a sealable container;
• b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid, said formulation being such that at least 95% of the paclitaxel potency is retained when said formulation is stored at 40° C. for seven days;
• c) placing said pharmaceutical formulation in said sealable container;
• d) sealing said sealable container;
• and
• e) storing said pharmaceutical formulation in said sealed container for at least seven days.

A method of formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the following steps:

• mixing paclitaxel with a pharmaceutically acceptable carrier material to form a pharmaceutical paclitaxel composition, the pH of said carrier material having been reduced to a level such that when paclitaxel is mixed therewith at least 95% of the paclitaxel potency is retained when the composition is stored at 40° C. for seven days;
• sealing said pharmaceutical paclitaxel composition in a sealable container;
• and
• storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.

A method of making a pharmaceutical paclitaxel composition, comprising the steps of:

• obtaining a pharmaceutically acceptable carrier material;
• reducing the pH of said carrier material to a level such that when paclitaxel is mixed therewith, at least 95% of the paclitaxel potency is retained when the resulting composition is stored at 40° C. for seven days;
• mixing paclitaxel with said reduced-pH carrier material to form a pharmaceutical paclitaxel composition;
• sealing said pharmaceutical paclitaxel composition in a sealable container;
• and
• storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.

A composition of matter produced by the process of:

• obtaining a pharmaceutically acceptable carrier material;
• reducing the pH of said carrier material to a level such that when paclitaxel is mixed therewith, at least 95% of the paclitaxel potency is retained when the resulting composition is stored at 40° C. for seven days;
• mixing paclitaxel with said reduced-pH carrier material to form a pharmaceutical paclitaxel composition;
• sealing said pharmaceutical paclitaxel composition in a sealable container;
• and
• storing said pharmaceutical paclitaxel composition in said sealed container for at least seven days.